Skip to main content
  • Valsartan Recall Expanded, FDA Investigating Products From Outside China

    Other ARB manufacturers subject to FDA investigation

    This story was originally published Aug. 10, 2018. As part of MedPage Today's year-end review of 2018's top stories, we are republishing it along with an update on what has happened since with contamination issues affecting valsartan and other angiotensin receptor blockers.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details